~ Trade alerts discuss changes to Tailwinds’ managed portfolios. They are available for premium subscribers only. The information contained here is not meant to be shared, especially with Company managements. Thank you. ~
I’ve added to Anixa (ANIX) and INmune Bio (INMB).
Anixa this morning announced that the FDA has accepted their IND for their breast cancer vaccine. Anixa will be entering human testing in the first half of 2021 and this should be a big value driver. If the data is positive, I expect to see them partner on the project around this time next year. Any partnership, post data, would likely be at a much higher market cap than the current $70 million. As well, I expect to see the IND for CAR-T filed and approved in Q1, which should also drive the value.
Regarding INMB, I think the data coming in January will be compelling and this stock could potentially double or more over the next 45 days. I want to be positioned here in a big way for this event.TW Research's Disclaimers & Disclosures: TW Research may have been compensated for writing this article. For a full list of disclaimers and disclosures, please visit http://